Simvastatin Added to Escitalopram in Obese Patients With Major Depression: A Rigorous RCT Shows No Antidepressant Benefit Despite Improved Cardiometabolic Markers

Simvastatin Added to Escitalopram in Obese Patients With Major Depression: A Rigorous RCT Shows No Antidepressant Benefit Despite Improved Cardiometabolic Markers

A multicenter double-blind RCT (n=160) found that 12 weeks of simvastatin (40 mg) added to escitalopram did not improve depressive symptoms versus placebo, although LDL, total cholesterol, and CRP were reduced.
Therapist-Guided Internet CBT Cuts Bulimia Episodes: A Japanese Randomized Trial with Promising Clinical Implications

Therapist-Guided Internet CBT Cuts Bulimia Episodes: A Japanese Randomized Trial with Promising Clinical Implications

A multicenter randomized trial in Japan found that a 12-week therapist-guided internet-based CBT program significantly reduced weekly bingeing and compensatory episodes in women with bulimia nervosa versus usual care (adjusted mean difference 9.84 episodes; Cohen d 0.73).
Dissecting Depression in Diabetes: Distinct Links of Somatic and Cognitive Symptoms with Inflammation and Insulin Resistance

Dissecting Depression in Diabetes: Distinct Links of Somatic and Cognitive Symptoms with Inflammation and Insulin Resistance

New GRADE sub-study reveals that somatic symptoms of depression, not cognitive-affective symptoms, are chiefly associated with inflammation and insulin resistance in type 2 diabetes, highlighting a pathophysiological bridge for targeted interventions.